OTLK

Outlook Therapeutics, Inc.

Healthcare
Biotechnology
$123M market cap

Forecast run · Sep 14, 2026Upside rank 126 of 3,136

Model Signal

ForecastQ Daily Probabilities

71.4%

50.1%

65.5%

Analyst Consensus

Recommendation2.43/5 Buy

Last price$0.66

Price target$2.80

Implied move+324.2%

Analysts14

ForecastQ Portfolios

OTLK is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.